|
Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study. |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Genmab; Johnson & Johnson; Millennium; Novartis; Oncopeptides |
Research Funding - Celgene; Millennium |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Genmab; Janssen-Cilag; Millennium; Novartis; Onyx; Sanofi |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Genmab; Janssen-Cilag; Millennium; Onyx |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Millennium; MSD; Novartis; Onyx |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Takeda |
|
|
|
Consulting or Advisory Role - Celgene |
Speakers' Bureau - Celgene |
Research Funding - Celgene |
|
|
Consulting or Advisory Role - Celgene; Roche |
Speakers' Bureau - Celgene; Novartis; Roche |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen-Cilag; Novartis; Takeda |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Takeda |
|
|
|
|
|
|
|
|
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda |